Note: Page numbers of article titles are in **boldface** type.

- Acetaminophen, for canine osteoarthritis, 853
- Aggrecan, in normal cartilage, 703
- Anamnesis, in osteoarthritis, 725–727
- Anconeal process, ununited, and osteoarthritis, 746–748
diagnosis of, 747, 801
pathogenesis of, 746
treatment of, 747–748
- Appendicular joints, arthrodesis of, for osteoarthritis, 933–935
- Arachidonic acid, metabolism of, in osteoarthritis, 844–845
- Arthritis, erosive, in cats, radiographic changes in, 949
inflammatory, in cats, causes of, 948
septic, osteoarthritis vs, 732
treatment of, nutrition in, 895–896
- Arthrocentesis, in osteoarthritis, 729
sites for, 731
- Arthrodesis, for osteoarthritis, 933–935
- Arthrography, for osteoarthritis diagnosis, 787–788
- Arthroplasty, excision, for osteoarthritis, 935–936
- Arthroscopy, for osteoarthritis, 936–937
- Articular cartilage, magnetic resonance imaging of, current status of, 794
normal, morphology of, 705
- Articular fractures, in dogs, and osteoarthritis, 760–764
- Articular surface, changes in, with osteoarthritis, 715
- Aspirin, for canine osteoarthritis, 850
role in developmental skeletal disease, 887–888
- Carprofen, for canine osteoarthritis, 849
- Carpus, osteoarthritis of, surgical treatment of, 940
- Cartilage, changes in, with osteoarthritis, 716
degeneration of, in osteoarthritis, factors in, 700
metabolism of, nonsteroidal anti-inflammatory drugs and, 845–846
normal, 701–714
articul ar, cross-section of, 706–707
morphology of, 705
chondrocytes in, 701–702
components of, 704
extracellular matrix in, 702–705
joint capsule and synovium, 710–713
joint lubrication, 713–714
subchondral bone, 708–710
resurfacing of, for osteoarthritis, 937–939
Cat(s), body composition of, scoring system for, 902
osteoarthritis in, 945–953. See also under *Osteoarthritis*.
- Cation-anion balance, dietary, role in developmental skeletal disease, 890
- Chondrocytes, changes in, with osteoarthritis, 938
grafting of, for osteoarthritis, 716
in normal cartilage, 701–702
- Codeine, with nonsteroidal anti-inflammatory drugs, for canine osteoarthritis, 854
- Collagen, in normal cartilage, 702–703
interaction with proteoglycan, 705–708
- Collateral ligaments, in dogs, injury of, and osteoarthritis, 772–773
- Computed tomography, advantages and disadvantages of, 785
for osteoarthritis diagnosis, 788–791
- Copper, role in developmental skeletal disease, 890–891
Eicosanoids, role in osteoarthritis, 842–844

Elbow joint, canine, collateral ligament injury of, and osteoarthritis, 772–773
dysplasia of, and osteoarthritis, 740–748
luxation of, and osteoarthritis, 766–767
osteochondritis of, diagnostic imaging of, 798–800
osteochondritis of, 737, 745–746
synovial hypertrophy in, 938
computed tomography of, in osteoarthritis, 792
feline, osteoarthritis of, 947
linear tomographic view of, in osteoarthritis, 787–788
osteochondritis of, surgical treatment of, 940

Electrotherapy, for osteoarthritis, 923–924
Energy intake, role in developmental skeletal disease, 885–887
Energy requirement, calculation of, 905
Environment, role in osteoarthritis management, 924–925
Etodolac, for canine osteoarthritis, 850–851
Excision arthroplasty, for osteoarthritis, 935–936
Exercise, and osteoarthritis, 913–930
as part of treatment, 916–917
benefits of, 916
relationship between, 915–916
type of, 917–919
Extracellular matrix, in normal cartilage, 702–705
collagen, 702–703
proteoglycans, 703–705

Fat, recommended levels for puppies, 893
Fatty acids, desaturation of, 897
immune response modulation by, 896–898
inflammation modulation by, 896–898
polyunsaturated, dietary manipulation of, for inflammation, 898–900
effect on rheumatoid arthritis, 899
potential effects on inflammation, 898
Feeding techniques, for nutritional management of osteoarthritis, 893–895
food-limited, 894–895
free-choice, 894
time-limited, 894
Femoral head, fractures of, in dogs, and osteoarthritis, 762–764
Femorotibial joint, flexion and extension angles in, with cranial cruciate ligament rupture, 836
flexion and extension movements of, 834
Fluoroscopy, for osteoarthritis diagnosis, 787
Force plate analysis, in osteoarthritis, 733
Force plate data, axes used for, in gait analysis, 827
Forepaw, osteoarthritis of, conventional radiographic imaging of, 783

Gait, general description of, 826–827
Gait analysis, canine, anticipated improvements in, 838
general description of, 826
in osteoarthritis, 728–729
kinematic, 832–833
basic, 833–835
in lameness, 835–837
study design and, 837–838
kinetic, 827–829
of pathologic gait, 831–832
study design and, 830–831
of canine lameness, 825–840
Gastrointestinal complications, with nonsteroidal anti-inflammatory drugs, 846–847
Genual joint, canine, osteoarthritis of, diagnostic imaging of, 805–807
German Shepherd, ununited anconeal process in, 747
Glycosaminoglycan, polysulfated, for osteoarthritis, 869–872
components of, 869
dosages of, 871
efficacy of, 871
mechanism of action of, 870
pharmacokinetics of, 869
safety of, 871–872
Goniometer, for range-of-motion measurement, 926
Ground reaction forces, in gait analysis, 828–829
Growth, role in developmental skeletal disease, 885–887

Heat, superficial, for osteoarthritis, 920
Hip dysplasia, canine, and osteoarthritis, 748–752
bilateral, 749, 751
diagnosis of, 749
diagnostic imaging of, 802, 804
gait analysis in, 752
genetics of, 752
kinematic analysis of, 835–837
pathogenesis of, 749
physical examination in, 750–752
radiography of, 750
treatment of, 752
congenital, nutrition and, 884
history in, 726
physical rehabilitation program for, 927–929
assessment, 927
maintenance, 928–929
therapy, 928
Hip joint, degenerative changes in, diagnostic imaging of, 803
laxity of, stress radiography of, 802
osteoarthritis of, diagnostic imaging of, 800–805
early signs in, 803
surgical treatment of, 940
total replacement of, 932–933
Hock, canine, osteoarthritis of, diagnostic imaging of, 805–809
osteochondritis of, 738
osteoarthritis of, surgical treatment of, 940
trauma to, stress radiography of, 789
Humeral condyle, canine, fractures of, and osteoarthritis, 760–762
Humeral joint, canine, osteoarthritis of, diagnostic imaging of, 796–798
Hyaluronan, for osteoarthritis, 867–869
components of, 867
efficacy of, 868
mechanism of action of, 868
pharmacokinetics of, 867
safety of, 868–869
Hydrotherapy, for osteoarthritis, 919, 921–922
Hypercalcitoninism, role in developmental skeletal disease, 888

Ibuprofen, for canine osteoarthritis, 851
Imaging modalities, for osteoarthritis, comparison of, 785
Immune response, modulation by fatty acids, 896–898
Inflammation, mediators of, production of, 843
modulation by fatty acids, 896–898
Intra-articular fractures, in dogs, and osteoarthritis, 750–762
complications of, 762
treatment of, 761–762

Joint, arthrodesis of, for osteoarthritis, 933–935
laxity of, with canine hip dysplasia, 750
lubrication of, with normal cartilage, 713–714
luxation of, in dogs, and osteoarthritis, 764–767
replacement of, total, for osteoarthritis, 932–933
Joint capsule, changes in, in osteoarthritis, 712–713
in normal cartilage, 710–713
Joint disease, degenerative, treatment of, nutrition in, 895–900
arthritis, 895–896
dietary manipulation of polyunsaturated fatty acids, 898–900
immune response and inflammation modulation, 896–898
Joint mouse, and osteoarthritis, in dogs, 736
Joint space, narrowing of, in osteoarthritis, conventional radiographic imaging of, 783–784, 795–796
Ketoprofen, for canine osteoarthritis, 851–852

Lameness, history in, 726
in canine patella luxation, 754
kinematic gait analysis in, 835–837
physical examination in, 728
with canine osteochondritis, 737, 807–808

Lateral collateral ligaments, in dogs, injury of, and osteoarthritis, 772
Ligament injuries, in dogs, and osteoarthritis, 767–773
Limb circumference, measurement of, 926
Limb symmetry, study of, 837
Linear tomography, for osteoarthritis diagnosis, 787–788
Lipoxygenase, activity of, in osteoarthritis, 842

Magnetic resonance imaging, advantages and disadvantages of, 785
for osteoarthritis diagnosis, 791–795
Massage, for osteoarthritis, 919
Meclofanamic acid, for canine osteoarthritis, 849
Medial collateral ligaments, in dogs, injury of, and osteoarthritis, 772–773
Medial coronoid process, fragmented, and osteoarthritis, 741–746
diagnostic imaging of, 798, 800
clinical signs of, 741
diagnosis of, 742
pathogenesis of, 741
radiographic findings in, 742–743
treatment of, 744–746
visualization of, 743–745
Meloxicam, for canine osteoarthritis, 853

Naproxen, for canine osteoarthritis, 852
Neuromuscular electrical stimulation, for osteoarthritis, 924
Neuropeptides, in nociception, 715
Nociception, chemical mediators for, 714 in osteoarthritis, 714–715
Nonsteroidal anti-inflammatory drugs, actions of, 846
and cartilage metabolism, 845–846
for canine osteoarthritis, 841–862
acetaminophen, 853
aspirin, 850
carprofen, 849
etodolac, 850–851
ibuprofen, 851
ketoprofen, 851–852
meclofanamic acid, 849
meloxicam, 853
naproxen, 852
narcotic combinations with, 853–854
phenylbutazone, 848–849
piroxicam, 852
role in overall management, 855–856
side effects of, 846–848
Nutritional management, of osteoarthritis, 883–911. See also under Osteoarthritis.

Obesity, diagnosis of, 901
health impact of, 901–903
management of, for osteoarthritis, 900–906
Osteoarthritis, 699–723
age and, 778
biochemical changes in, 717
cartilage changes in, 706–707
cartilage degeneration in, factors in, 700
classification of, 778
clinical evaluation in, 725–734
corticosteroids for, 854–855
definition of, 699
diagnostic imaging of, 777–814
aim of, 778
arthrography, 787–788
computed tomography, 788–791
conventional radiography, 779–784
fluoroscopy, 787
linear tomography, 787
magnetic resonance imaging, 791–795
magnification radiography, 784–787
measurement of osteoarthritic changes, 795–796
methods of, 779–796
stress radiography, 787
disease-modifying agents for, oral, 863–867
composition of, 864
efficacy of, 866
mechanism of action of, 865
pharmacokinetics of, 864–865
safety of, 866
slow-acting, 863–881
etiopathogenesis of, 715–718
exercise and, 915–919. See also Exercise. fragmented medial coronoid process and, 741–746
history in, 727
hyaluronan for, 867–869
in cat, 945–953
clinical manifestations of, 946
diagnosis of, 946–950
drugs for, 951
incidence of, 945–946
inflammatory arthritis vs, 949
management of, 950-952
nutritional supplements for, 951
in dogs, acquired conditions leading to, 759-775
articar fractures, 760-764
muscle ligation, 764-767
ligament injuries, 767-773
pathophysiology of, 759-760
congenital conditions leading to, 735-758
elbow dysplasia, 740-748
hip dysplasia, 748-752
osteoarthritis, 735-740
patella luxation, 753-755
laboratory examinations in, 729-733
management of, 841-862
medical, clinical trials of, 815-823
outcome or response measurements, 817-821
agent influence, 821
disease definition, 817
disease-specific, 817-818
measurement characteristics, 819-820
study population influence, 820-821
overview of, 816-817
nutritional, 883-911
feeding techniques, 893-895. See also Feeding techniques.
role of environment in, 924-925
nociception in, 714-715
of specific joints, diagnostic imaging of, 796-809
canine elbow (cubital) joint, 798-800
canine hock (tarsocrural) joint, 805-809
canine shoulder (humeral) joint, 796-798
canine stifle (genua) joint, 805-807
hip (coxal) joint, 800-805
osteophytes and, 710
pentosan polysulfate for, 872-873
physical agents for, 920-924. See also Physical agents.
physical examination in, 727-729
polysulfated glycosaminoglycan for, 869-872
predisposing causes of, methods of evaluation of, 779-796
radiography in, 729
subchondral bone changes in, 709
tetracyclines for, 874-876
treatment of, exercise and physical modalities in, 913-930
surgical, 931-944
algorithm for, 939
arthrodesis, 933-935
arthroscopy, 936-937
cartilage resurfacing, 937-939
excision arthroplasty, 935-936
options in, 940
selection of, 939-940
total joint replacement, 932-933
ununited anconeal process and, 746-748
weight control for, 900-906
Osteochondral flap, reattachment of, in dogs, 740
Osteochondritis, arthroscopic treatment of, 937
diagnostic imaging of, 797
in dogs, and osteoarthritis, 735-740
elbow, 737, 745-746
hock, 738
radiography of, 739
shoulder, 736
stifle, 738
surgical removal of, 739
magnetic resonance imaging of, 794
Osteochondrosis, diagnostic imaging of, 797
nutrition and, 884-885
of humeral head, magnification radiography of, 786
Osteophytes, in osteoarthritis, 710, 799
conventional radiographic imaging of, 782-783
Pain, with osteoarthritis, 714-715
identification of, 727
Pancarpal arthodesis, for osteoarthritis, 934
Patella luxation, in dogs, and osteoarthritis, 735-755
diagnosis of, 753
joint capsule imbrication for, 755
pathophysiology of, 753
treatment of, 754-755
Pentosan polysulfate, for osteoarthritis, 872-873
components of, 872
mechanism of action of, 873
pharmacokinetics of, 872-873
safety and efficacy of, 873
Phenylbutazone, for canine osteoarthritis, 848-849
Phosphorus, recommended levels for puppies, 893
role in developmental skeletal disease, 889
Physical agents, for osteoarthritis, 913-930
cryotherapy, 920-921
electrotherapy, 923-924
hydrotherapy/swimming, 921-922
outcome of, limitations in assessing, 925-927
superficial heat, 920
ultrasound and diathermy, 922-923
Physical rehabilitation, in veterinary medicine, 914–915

Piroxicam, for canine osteoarthritis, 852

Polysulfated glycosaminoglycan, for osteoarthritis, 869–872

Prostaglandin E₂, role in osteoarthritis, 843

Proteases, degradative, with osteoarthritis, 716, 718

Protein, recommended levels for puppies, 893

Proteoglycans, depletion of, with osteoarthritis, 716

in normal cartilage, 703–705

interaction with collagen, 705–708

Radiography, conventional, advantages and disadvantages of, 785

for osteoarthritis diagnosis, 779–784

magnification, for osteoarthritis diagnosis, 784–787

microfocal, for osteoarthritis diagnosis, 785

stress, for osteoarthritis diagnosis, 787

Recommended nutrient intake, and developmental skeletal disease, 893

Renal toxicity, with nonsteroidal anti-inflammatory drugs, 847

Scintigraphy, advantages and disadvantages of, 785

Set point, in weight loss management, 903–904

Shoulder, arthrodesis of, for osteoarthritis, 934

canine, osteoarthritis of, diagnostic imaging of, 796–798

osteochondritis of, 736

normal, radiography of, 781

osteoarthritis of, arthrography of, 791

surgical treatment of, 940

with lameness, arthrography of, 790

Skeletal disease, developmental, nutrition and, 883–884

recommended nutrient intake and, 893

risk factors for, 885–888

B vitamins, 892–893

calcium, 887–888

copper, 890–891

dietary cation-anion balance, 890

energy/growth, 885–887

hypercalcitoninism, 888

phosphorus, 889

protein, 889

vitamin A, 892

vitamin C, 892

vitamin D, 891–892

zinc, 891

Stifle, collateral ligament injury of, and osteoarthritis, 773

magnetic resonance imaging of, in osteoarthritis, 793

normal, radiography of, 780

osteoarthritis of, diagnostic imaging of, 805–807

surgical treatment of, 940

osteochondritis of, 738

passive range-of-motion exercise of, 918

Stress radiography, for osteoarthritis diagnosis, 787, 789

Subchondral bone, in normal cartilage, 708–710

sclerosis of, in osteoarthritis, 784, 799

Surgical treatment, of osteoarthritis, 931–944. See also under Osteoarthritis.

Swimming, for osteoarthritis, 921–922

Synovectomy, partial, for osteoarthritis, 937

Synovial fluid analysis, in osteoarthritis, 729–732

findings in, 730

in cats, 947

Synovial membrane, biopsy of, in osteoarthritis, 733

Synovium, in normal cartilage, 710–713

in osteoarthritis, 711–712

Tarsal joint, flexion and extension movements of, 834

Tarsocrural joint, canine, osteoarthritis of, diagnostic imaging of, 805–809

Tenosynovitis, with canine shoulder joint osteoarthritis, diagnostic imaging of, 797

Tetracyclines, for osteoarthritis, 874–876

efficacy and safety of, 875

mechanism of action of, 874–875

pharmacokinetics of, 874

Tibial tubercle, transposition of, in canine patella luxation, 754

Tomography, linear, for osteoarthritis diagnosis, 787

Ultrasound, for osteoarthritis treatment, 922–923

Veterinary medicine, physical rehabilitation in, 914–915

Vitamin A, role in developmental skeletal disease, 892
<table>
<thead>
<tr>
<th>Topic</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vitamin C, role in developmental skeletal disease</td>
<td>892</td>
</tr>
<tr>
<td>Vitamin D, role in developmental skeletal disease</td>
<td>891–892</td>
</tr>
<tr>
<td>Walking, for osteoarthritis</td>
<td>918</td>
</tr>
<tr>
<td>Water therapy, for osteoarthritis</td>
<td>919, 921–922</td>
</tr>
<tr>
<td>Weight control, for osteoarthritis</td>
<td>900–906</td>
</tr>
<tr>
<td>Weight loss, plan to succeed</td>
<td>903–906</td>
</tr>
<tr>
<td>reasons for failure</td>
<td>903–906</td>
</tr>
<tr>
<td>Zinc, role in developmental skeletal disease</td>
<td>891</td>
</tr>
<tr>
<td>disease factors</td>
<td>904</td>
</tr>
<tr>
<td>inaccurate estimation of energy requirement</td>
<td>905–906</td>
</tr>
<tr>
<td>inaccurate estimation of ideal body weight</td>
<td>905</td>
</tr>
<tr>
<td>noncompliance</td>
<td>904</td>
</tr>
<tr>
<td>set point</td>
<td>903–904</td>
</tr>
<tr>
<td>traditional management of</td>
<td>903</td>
</tr>
</tbody>
</table>